This trial is evaluating whether Single Photon Emission Computed Tomography will improve 1 primary outcome, 3 secondary outcomes, and 2 other outcomes in patients with refractory, primary Cutaneous T-Cell Non-Hodgkin Lymphoma. Measurement will happen over the course of From registration to disease progression or death due to any cause, assessed up to 2 years.
This trial requires 65 total participants across 3 different treatment groups
This trial involves 3 different treatments. Single Photon Emission Computed Tomography is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Recent findings demonstrate the need to identify effective treatments for R/PCNTL. There appears to be a high rate of resistance to treatment even when combination therapies are offered, indicating an optimal therapeutic strategy requires development." - Anonymous Online Contributor
"Primary PCTCLs are an aggressive, chemoresistant and heterogeneous group of neoplasms and their occurrence is uncommon. For many patients with localized or regional PCTCLs the best clinical response to systemic chemotherapy is obtained with localized or regional high-dose radiotherapy alone or in conjunction with localized or regional immunotherapy." - Anonymous Online Contributor
"Data from a recent study of this study suggest that t-cell-based therapy is a reliable option for the treatment of refractory, primary cutaneous T-cell lymphomas, especially in patients with cutaneous T-cell lymphomas who lack traditional systemic therapy. However, longer follow-up is warranted before definitive conclusions can be made as to the best therapeutic approach." - Anonymous Online Contributor
"As of July 2013, a total of 6 SPS trials had been conducted with only a single trial comparing multiple active agents to single agents. This low level of evidence does not allow firm conclusions to be drawn in patients with PCNSCL." - Anonymous Online Contributor
"Currently there are no studies that have identified biomarkers for refractory, primary cutaneous T-cell lymphomas. The best option for managing refractory cutaneous lymphomas is to administer chemotherapy with intralesional steroids/systemic/immunotherapy (e.g., methotrexate, rituximab, vincristine) with or without biologic therapies. This combination results in a median PFS of 16 months (range 1.5-36.5 months). The use immunotherapy in combination with chemotherapy can enhance the effect of the therapies and reduces the number of treatments, time to complete remission, and side effects." - Anonymous Online Contributor
"With the new NCI classification of DLBCL, the median age at the time of DLBCL diagnosis was 68 years with a median survival of 16 months. Since the time leading up to the revision of the current NCI classification of DLBCL, the median age has dropped to 60.5 years in the 2013-2015 cohort (n = 23,650) and 59 years (n = 10,532) from the first quarter (January) to 2017-2018. Patients younger than age 40 years accounted for 43% of patients in this cohort versus 30% of all patients diagnosed with DLBCL over the last decade. This has likely been because of advances in treatment of older patients for aggressive B-cell malignancies." - Anonymous Online Contributor
"This report describes a patient with refractory PEZ. PEZ should be routinely included in the differential diagnosis of t-cell lymphoma irrespective of location. The presentation in the lower limb may mimic that of mycosis fungoides. This case illustrates the importance of close follow-up in the early stages of t-cell lymphoma, as its behaviour can alter quickly. Early diagnosis is critical for guiding appropriate therapy." - Anonymous Online Contributor
"The most common non-Hodgkin lymphoma in this study was chronic mycosis fungoides in children and adolescents. The most common subtype of cutaneous T-cell lymphomas in children and adolescents was mycosis fungoides/Sezary syndrome. About 50% of patients with Sezary syndrome were older than 40 years old. The most common presenting feature was enlargement of lymph nodes." - Anonymous Online Contributor
"T-cells in ECP infiltrate cutaneous mucosa, bone, brain, and liver. Involvement of cutaneous mucosa in diffuse infiltration without follicle formation is highly unusual. A significant proportion of our patients, regardless of age or stage, have diffuse necrosis of the overlying skin without follicle formation (as previously reported). Many of these patients are in their 40s. Although their exact pathology remains inconclusive, these patients would be eligible for an aggressive treatment regimen in most cases." - Anonymous Online Contributor
"Single photon emission computed tomographic imaging can frequently locate regions of increased uptake by a small percentage of t(i)-cells, particularly in follicular variants of low-grade CTCL. In t(i)TLC, the high uptake of fluorodeoxyglucose is limited to anatomically connected regions of FDG-PET positive tissue. This indicates that single photon emission computed tomographic imaging is a useful tool, particularly in t(i)TLC." - Anonymous Online Contributor
"We found that many patients have an abnormal SPECT scan. Some physicians consider the scan only for those patients who may benefit from treatment, and not to ensure an accurate diagnosis. We find that most of these exams result in no change or a less favorable clinical result. Because of this, the presence of an abnormal SPECT examination may not be as important as previously thought." - Anonymous Online Contributor
"In the majority of cases, SLEP was not used in combination with other treatments. Only one third of the patients were treated with standard SLEP. It is difficult to make conclusions regarding the use of SLEP because only a limited number of patients could be reliably identified. We found that SLEP is less frequently used in daily clinical practice than expected." - Anonymous Online Contributor